Micoderil, 1% drops

Mikoderil ^®  is an antifungal drug for external use, the active ingredient of which is naftifine. Naftifine is an antifungal agent belonging to the allylamine class. The mechanism of action is associated with inhibition of squalene-2,3-epoxidase, which leads to a decrease in the formation of ergosterol, which is part of the cell wall of the fungus. Naftifine, affecting squalene epoxidase, does not affect the cytochrome P-450 system.

Naftifine is active against dermatophytes such as Trichophyton, Epidermophyton, Microsporum, yeast and yeast-like fungi (Candidaspp., Pityrosporum), molds (Aspergillus) and other fungi (for example Sporothrixschenckii). In relation to dermatophytes and aspergillus, naftifine has a fungicidal effect.

In relation to yeast fungi, the preparation exhibits fungicidal or fungistatic activity, depending on the strain of the microorganism. Naftifine has antibacterial activity against gram-positive and gram-negative microorganisms that cause secondary bacterial infections.

Naftifine has an anti-inflammatory effect, which promotes the rapid disappearance of symptoms of inflammation, especially itching.

Pharmacokinetics

• Fungal infections of smooth skin and skin folds (tinea corporis, tinea inquinalis);
• interdigital mycoses (tinea manum, tinea pedum);
• fungal infections of the nails (onychomycosis);
• candidiasis of the skin;
• pityriasis versicolor;
• inflammatory dermatomycosis (with or without itching).

• Hypersensitivity to naftifine or propylene glycol;
• pregnancy and lactation (the safety and efficacy of the drug in this category of patients has not been studied);
• application of the drug to the wound surface.

With caution: childhood (clinical experience is limited).

In some cases, local reactions can be observed: dry skin, skin flushing and burning.

Side effects are reversible and do not require treatment withdrawal.

If any of the side effects indicated in the instructions are aggravated, or any other side effects not indicated in the instructions are noted, you should immediately inform your doctor about it.

Interaction with other drugs has not been studied.

Outwardly.

With dermatomycosis and candidiasis of the skin

Mikoderil, a solution for external use, 1% is applied once a day to the affected skin surface and adjacent areas after thorough cleaning and drying, capturing approximately 1 cm of healthy skin along the edges of the affected area.

Duration of treatment: with dermatomycosis - 2-4 weeks (if necessary - up to 8 weeks), with candidiasis - 4 weeks.

With nail lesions (onychomycosis)

Before the first use of the drug, the affected part of the nail is removed as much as possible with scissors and a nail file. The drug is used 2 times a day, the duration of treatment for onychomycosis is up to 6 months.

To prevent recurrence of infection, the drug should be continued for at least 2 weeks after the disappearance of clinical symptoms.

No cases of overdose have been reported.

Mikoderil, solution for external use, 1% is effective in the treatment of mycoses affecting areas of the skin with hyperkeratosis, as well as in areas of hair growth.

Course treatment is required.

Avoid contact with eyes and open wounds.

Use in pediatrics

The drug should be used with caution in children.

Influence on the ability to drive vehicles and other mechanisms that require increased concentration of attention

Mikoderil, solution for external use, 1% does not adversely affect the ability to drive vehicles and perform other activities that require concentration and psychomotor speed.

Solution for external use.